http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0121067-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a89a4da6d21c067a4c4146337fb3ba83
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
filingDate 1984-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1c332301983f9fcdcb81d25d5c95a66
publicationDate 1984-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0121067-A1
titleOfInvention Process for the preparation of oligosaccharide fractions having pharmacological properties by chemical degradation of heparin
abstract Process for the preparation of oligosaccharides and oligosaccharide fractions by degradation of heparin, which comprises submitting to incubation an aqueous solution of heparin containing from 5 to 30 g of heparin/liter in the presence of 4-50 m.moles/l of cupric acetate and 50-300 m.moles/l of hydrogen peroxide, at a temperature of 40 DEG -50 DEG C., for 20-24 hours and keeping the pH at a value of 7.8 by means of sodium acetate. The obtained products show a high inhibiting property of the Xa factor, a high antithrombotic activity and a very modest anticoagulant activity; therefore they are very interesting for a possible utilization as drugs in the antithrombotic treatment, practically free from any risk of haemorrhages.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9387256-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4987222-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8592393-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8569262-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10016449-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5084564-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9212233-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5767269-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107090052-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9358252-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10017585-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5744457-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4973580-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5763427-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9351992-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6001820-A
priorityDate 1983-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393724
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128317520
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53970987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135955169
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441477
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54676860
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID446102
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393810
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135927382
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57092463
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136230068
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129125189
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3246006
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24180930
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128643097
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25200375

Total number of triples: 49.